Alligator Bioscience AB (FRA:7AL)
€ 0.0215 -0.023 (-51.69%) Market Cap: 17.75 Mil Enterprise Value: 14.46 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Alligator Bioscience AB R&D Market Update Transcript

Aug 27, 2020 / 12:00PM GMT
Release Date Price: €0.542007 (-0.41%)
Unidentified Participant

Greetings from the Biostock studio here at medical village in Lund, we're pleased to invite you to this R & D market update event featuring Alligator Bioscience a Loon-based biotech company developing immune-oncology treatments. The program for today's event will begin with Alligator Biosciences' CEO, who will talk more about eight or 15 metas alimon. At 2:15, we will hear from the company, CEO Malin Carlsson who will discuss instead of 2017 and its development track.

Then at 2:30, we will be joined via Zoom by professor Ignacio Melero from the University of Nevada in Spain. He will talk about 4-1BB as an attractive target in immuno-oncology. At 2:45, the program will finish off with a Q&A session and conclude at three. So now I leave the words to Pat Nalon and Marlon Carlson. Welcome both.

Per NorlÃ;n
Alligator Bioscience AB - CEO

© -

Thank you. So again, welcome. This is an R&D update, and we are today going to focus on our clinical programs on the actual drug candidates, the properties and how we're going to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot